A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease
- PMID: 9613719
A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease
Abstract
GDNF is a pleitropic neurotrophic factor which stimulates the dopaminergic phenotype in vitro and in vivo by way of activation of the GDNF/RET receptor complex. The pharmacologic profile of GDNF in two well-characterized animal models of Parkinson's disease suggests that the molecule may be useful in the treatment of neurodegenerative diseases involving dopaminergic dysfunction such as Parkinson's disease. This review summarizes the preclinical development path which was taken to develop GDNF as a novel therapeutic approach to treat Parkinson's disease based on GDNF's ability to regenerate dopamine neurons, including a description of the pharmacologic/biologic activities of GDNF. The overall aim will be to discuss these issues in the context of their potential therapeutic usefulness of GDNF to treat Parkinson's disease.
Similar articles
-
Glial cell line-derived neurotrophic factor: a novel therapeutic approach to treat motor dysfunction in Parkinson's disease.Exp Neurol. 1997 Mar;144(1):29-34. doi: 10.1006/exnr.1996.6384. Exp Neurol. 1997. PMID: 9126148 Review.
-
Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.Ann Neurol. 1997 Aug;42(2):208-14. doi: 10.1002/ana.410420212. Ann Neurol. 1997. PMID: 9266731
-
Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.Exp Neurol. 2002 Apr;174(2):230-42. doi: 10.1006/exnr.2002.7877. Exp Neurol. 2002. PMID: 11922664
-
Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF.Exp Neurol. 2000 Jul;164(1):15-24. doi: 10.1006/exnr.2000.7409. Exp Neurol. 2000. PMID: 10877911
-
The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.Exp Neurol. 1993 Nov;124(1):103-18. doi: 10.1006/exnr.1993.1181. Exp Neurol. 1993. PMID: 8282068 Review.
Cited by
-
Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons.J Neurosci. 1999 Feb 15;19(4):1284-93. doi: 10.1523/JNEUROSCI.19-04-01284.1999. J Neurosci. 1999. PMID: 9952406 Free PMC article.
-
Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.J Neurosci. 2001 Jun 15;21(12):4427-35. doi: 10.1523/JNEUROSCI.21-12-04427.2001. J Neurosci. 2001. PMID: 11404429 Free PMC article.
-
Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications.Pharmaceuticals (Basel). 2012 Jun 4;5(6):553-90. doi: 10.3390/ph5060553. Pharmaceuticals (Basel). 2012. PMID: 24281662 Free PMC article.